HSK44459 vs Nerandomilast (Jascayd)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Idiopathic Pulmonary Fibrosis

Shared mechanism: PDE4B · full Idiopathic Pulmonary Fibrosis pipeline

HSK44459

Developed by Haisco Pharmaceutical Group

Phase 3 in Idiopathic Pulmonary Fibrosissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2028 · NCT07519070 (registry estimate)

No aligned efficacy figure on record for this race.

Nerandomilast (Jascayd)

Marketed by Boehringer Ingelheim

Approved in Idiopathic Pulmonary Fibrosissmall molecule
Reliable signal

NCT05321069 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial with 1,177 participants and a hard physiological primary endpoint: change in lung function measured by forced vital capacity. The primary endpoint was statistically significant in favor of nerandomilast for both 9 mg and 18 mg doses versus placebo.

Next expected readout: April 2027 · NCT06238622 (registry estimate)

Reported efficacy

Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) (met)

Result source: NCT05321069

Results for Idiopathic Pulmonary Fibrosis

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

HSK44459: no structured comparison results are available for Idiopathic Pulmonary Fibrosis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nerandomilast (Jascayd)
Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) NCT05321069 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88) NCT04419506 · Phase 2 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HSK44459's landscape · Nerandomilast (Jascayd)'s landscape